Blog
RSS FeedPosted by Michael Wonder on 03 Mar 2026
Alnylam receives positive recommendation from Canada's Drug Agency for the public reimbursement of Amvuttra (vutrisiran injection), the first and only RNAi therapeutic for the treatment of cardiomyopathy in adult patients with ATTR amyloidosis
2 March 2026 - Alnylam Canada is pleased to announce it has received a positive recommendation from Canada's Drug Agency for ...
Posted by Michael Wonder on 21 Feb 2026
Canada's public drug plans shouldn't cover new Alzheimer's drug, agency says
19 February 2026 - Lecanemab, also known as Leqembi, is approved to treat mild cognitive impairment, early Alzheimer's. ...
Posted by Michael Wonder on 06 Dec 2025
New resource: understanding Canada’s drug approval and reimbursement pathway
3 December 2025 - Understanding how new oncology and non-oncology drugs move through Canada’s regulatory and drug access pathways can ...
Posted by Michael Wonder on 17 Oct 2025
Health Economics Methods Advisory Group releases draft report: asssessing treatment benefits in health technology assessment decision-making
9 October 2025 - Public comment period now open until 30 October 2025. ...
Posted by Michael Wonder on 16 Sep 2025
The use of real world evidence among health care payers: a scoping review
12 September 2025 - Real world evidence is increasingly used to assess and make regulatory decisions on health technologies. However, its ...
Posted by Michael Wonder on 30 Jul 2025
CDA issues positive reimbursement recommendation for Skyclarys (omaveloxolone), the only Health Canada approved treatment for managing Friedreich ataxia
29 July 2025 - Biogen Canada is pleased to announce a significant step forward for Canadians living with Friedreich ataxia, ...
Posted by Michael Wonder on 06 Jun 2025
Biogen disappointed by INESSS recommendation on Skyclarys and its impact on Quebec patients with Friedreich ataxia
5 June 2025 - Biogen Canada is disappointed by INESSS's recommendation against listing Skyclarys (omaveloxolone), despite its therapeutic potential for ...
Posted by Michael Wonder on 28 Apr 2025
New position statement aims to guide the use of AI methods in health technology assessment
25 April 2025 - Canada’s Drug Agency has published a new position statement on the use of artificial intelligence methods ...
Posted by Michael Wonder on 18 Apr 2025
Canada’s Drug Agency announces new 5 year strategic plan
17 April 2025 - Canada’s Drug Agency announces a new 5-year strategic plan, Insight to Impact 2025–2030. ...
Posted by Michael Wonder on 03 Mar 2025
Canada’s Drug Agency publishes new guidance for rare disease registries in Canada
28 February 2025 - On Rare Disease Day — a global event dedicated to raising awareness for the millions of ...
Posted by Michael Wonder on 13 Jan 2025
International collaboration provides new guidance on the use of surrogate endpoints in cost effectiveness analysis
9 January 2025 - Recommendations will help organisations that appraise new drugs establish whether their use will result in longer-term ...
Posted by Michael Wonder on 05 Dec 2024
Canada’s Drug Agency launches consultation on methods guide
28 November 2024 - Canada’s Drug Agency is launching a consultation on its first ever methods guide. ...
Posted by Michael Wonder on 09 Nov 2024
Canada's Drug Agency recommends Winrevair (sotatercept) for reimbursement
8 November 2024 - Merck announced that Canada's Drug Agency has recommended Winrevair (sotatercept) for reimbursement in combination with standard ...
Posted by Michael Wonder on 07 Oct 2024
New flexible service through our scientific advice program
26 September 2024 - Drug sponsors can now request a flexible service through our scientific advice program that can include ...
Posted by Michael Wonder on 05 Sep 2024
Today’s the day: we are officially Canada’s Drug Agency
5 September 2024 - We are expanding on our existing mandate and functions — which span drugs, medical devices, and clinical ...